PACB - Pacific Biosciences of California, Inc.
7.51 0.00 (0.00%)
After hours: 7:28PM EST
| Previous Close | 7.54 |
| Open | 7.55 |
| Bid | 7.51 x 800 |
| Ask | 7.55 x 3000 |
| Day's Range | 7.50 - 7.56 |
| 52 Week Range | 2.02 - 7.84 |
| Volume | 3,099,770 |
| Avg. Volume | 3,640,665 |
| Market Cap | 1.118B |
| Beta (3Y Monthly) | 1.21 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.73 |
| Earnings Date | Jan 30, 2019 - Feb 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.42 |
- Zacks•3 days ago
Here's Why You Should Invest in Illumina (ILMN) Stock Now
llumina (ILMN) set to take over peer in a $1.2-billion deal, which will strengthen its position in the genomics market.
- Zacks•4 days ago
Pacific Biosciences Offers Insights on Aedes aegypti Genome
Pacific Biosciences (PACB) uses its flagship Single Molecule, Real-Time technology to sequence the highest quality genome assembly for the Aedes aegypti mosquito.
- Motley Fool•5 days ago
Is This the Real Reason Illumina Acquired Pacific Biosciences?
The $1.2 billion acquisition will combine the two leading DNA sequencing technology platforms, but the battle for the future of DNA sequencing is just getting started.
- GlobeNewswire•5 days ago
PacBio’s SMRT Sequencing Provides Unprecedented Insight into Genome of Disease-causing Mosquito
Pacific Biosciences of California Inc., (PACB), the leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that an international team of scientists have published the highest quality genome assembly to date of the Aedes aegypti mosquito genome using its Single Molecule, Real-Time (SMRT®) technology. “The high-quality genome assembly and annotation described here will enable major advances in mosquito biology and has already allowed us to carry out a number of experiments that were previously impossible,” the authors write.
- ACCESSWIRE•8 days ago
Pacific Biosciences Agrees to be Acquired in an All Cash Transaction, Analysts Review
NEW YORK, NY / ACCESSWIRE / November 12, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Pacific Biosciences of California, Inc. (PACB), a company that offers sequencing systems to help scientists resolve genetically complex problems. PacBio® sequencing systems, including consumables and software, provide a simple and fast end-to-end workflow for SMRT sequencing. On November 1, 2018, the Company announced they had signed an agreement for Illumina to acquire Pacific Biosciences in an all-cash transaction.
- Motley Fool•11 days ago
Why Alkermes' Depression Drug Stumbled, and How Illumina Plans to Profit From M&A
Here's what derailed the drug, and why Illumina is paying $1.2 billion to acquire Pacific Biosciences.
- Zacks•12 days ago
Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y
Pacific Biosciences (PACB) is getting acquired by Illumina (ILMN) by mid-2019.
- Zacks•12 days ago
Illumina (ILMN) Inks $1.2B Deal to Buy Pacific Biosciences
Illumina (ILMN) taking out on its peer, in the $1.2-billion acquisition deal, will further strengthen the position of the former in the genomics market.
- GlobeNewswire•13 days ago
Consolidated Research: 2018 Summary Expectations for Pacific Biosciences of California, NXP Semiconductors N.V., Consolidated Communications, Alexander & Baldwin, Willdan Group, and OneMain — Fundamental Analysis, Key Performance Indications
NEW YORK, Nov. 07, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- ACCESSWIRE•13 days ago
Big Biotech May Be After These Technologies
HENDERSON, NV / ACCESSWIRE / November 6, 2018 / Big biotech stock buybacks "have destroyed more than $12 billion in value, and generated no positive return in total, at least as a portfolio investment," ...
Market Realist•15 days agoPacific Biosciences of California Rose 67.63% on November 2
On November 2, Pacific Biosciences of California (PACB) closed at $7.56, which was 67.63% higher than its previous closing price. On November 1, Illumina (ILMN) released a press release announcing the acquisition of Pacific Biosciences of California for a total consideration of $1.2 billion. According to the press release, Illumina expects to close the deal by mid-2019. The acquisition is expected to strengthen Illumina’s position in the genome sequencing market.
- Motley Fool•16 days ago
Here's Why Illimuna Just Bought Its Biggest Competitor
Illumina surprised investors this week by announcing it's buying Pacific Biosciences. Here's how the deal could move the needle for investors.
- Associated Press•17 days ago
Apple and Kraft Heinz drop while Starbucks and Symantec rise
Stocks that moved substantially or traded heavily on Friday: Apple Inc., down $14.74 to $207.48 The company's revenue forecast disappointed Wall Street and it said it will stop reporting quarterly iPhone ...
Motley Fool•17 days agoWhy Newell Brands, VeriSign, and Pacific Biosciences of California Jumped Today
Find out which of these stocks got a buyout bid.
- Motley Fool•17 days ago
Why Pacific Biosciences of California Stock Is Skyrocketing Today
A $1.2 billion acquisition of the gene-sequencing company sends its shares into orbit.
- ACCESSWIRE•17 days ago
Surge In Healthcare Growth Sees Rally In These 3 Stocks On Friday
CORAL GABLES, FL / ACCESSWIRE / November 2, 2018 / Over the last few days, prices of the iShares Nasdaq Biotech ETF (IBB) as well as the SPDR Healthcare ETF (XLV) have recovered from previous lows this week. Premier Health Group, Inc. (PHGRF)(PHGI.CN) saw its shares trade higher on Thursday. Shares of Premier Health Group, Inc. (PHGRF)(PHGI.CN) have begun to trade on the OTC Markets Group Inc.'s OTCQB Venture Market in the United States, under the symbol PHGRF in late October, and are now Depository Trust Company eligible, effective Oct. 22, 2018.
- Benzinga•18 days ago
Illumina Buys Rival Pacific Biosciences In $1.2B Deal
Shares of Pacific Biosciences of California (NASDAQ: PACB ), a developer of systems for gene sequencing, are soaring to a two-year high in pre-market trading. What Happened Pacific Biosciences announced ...
- Benzinga•18 days ago
The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 1) Gritstone Oncology Inc (NASDAQ: GRTS ) Repligen Corporation ...
- Zacks•18 days ago
Pacific Biosciences of California (PACB) Reports Q3 Loss, Lags Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of -18.75% and -17.29%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Motley Fool•18 days ago
Pacific Biosciences of California Reports a Dismal Quarter -- and a Delightful Acquisition
A pending buyout by Illumina overshadows the gene-sequencing company's third-quarter performance.
- Associated Press•18 days ago
Pacific Biosciences: 3Q Earnings Snapshot
On a per-share basis, the Menlo Park, California-based company said it had a loss of 19 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
- American City Business Journals•18 days ago
Illumina Inc. to buy Menlo Park-based biotech firm for $1.2 billion
Illumina Inc. said it plans to purchase Menlo Park-based Pacific Biosciences of California Inc. for approximately $1.2 billion in a move to accelerate its scientific discovery and long-read sequencing, the company said Thursday. The all-cash transaction was set at a price of $8 per Pacific Biosciences share, with the price representing a 71 percent premium to Pacific Biosciences’ 30 trading day price, according to a statement. Illumina hopes to use the acquisition to integrate workflows and technologies "to help researchers advance their discoveries faster and clinicians offer new tests economically." “PacBio’s unmatched accuracy mirrors that of Illumina’s in short-read sequencing,” said Francis deSouza, Illumina’s president and CEO, in the statement.
- Reuters•18 days ago
Illumina to buy rival Pacific Biosciences in $1.2 bln deal
Gene sequencing company Illumina Inc said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20181101:nBw18KCRQa on Thursday it plans to buy smaller rival Pacific Biosciences of California Inc in an all-cash deal valued at $1.2 billion, expanding its capabilities as the market grows. Illumina's offer of $8 per Pacific share represents a premium of about 77 percent to Pacific's Thursday close. Illumina is a major player in the nascent gene sequencing space and last year unveiled its NovaSeq sequencing platform, which is designed to deliver faster and cheaper gene sequencing over existing models.
- Reuters•18 days ago
Gene sequencing company Illumina to buy Pacific Biosciences in $1.2 billion deal
(Reuters) - Gene sequencing company Illumina Inc (ILMN.O) said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20181101:nBw18KCRQa on Thursday it plans to buy Pacific ...
- MarketWatch•18 days ago
Illumina to acquire Pacific Biosciences for $1.2 billion in cash
Illumina Inc. said late Thursday that it plans to acquire Pacific Biosciences of California Inc. for $1.2 billion. Illumina stock was down less than 1% in after hours trading. Illumina said it will pay $8 per share in an all-cash deal. "[Pacific Biosciences] unmatched accuracy mirrors that of Illumina's in short-read sequencing," Illumina Chief Executive Francis deSouza said. "Combining the two technologies positions us to reach more applications, accelerate the pace of genomic discovery and bolster our innovation engine which has been a hallmark of Illumina since our inception." Goldman Sachs is serving as a financial advisor for the transaction. Illumina will hold a conference call at 5 p.m. Eastern time to discuss the transaction. Illumina stock is up 43% this year as the S&P 500 index has gained 2.5%.
